AhR agonist effects on NEP expression in N2a cells

Exploratory Score: 0.900 Price: $0.50 Alzheimer's disease N2a cells Status: proposed

What This Experiment Tests

Exploratory experiment designed to discover new patterns targeting NEP in N2a cells. Primary outcome: NEP expression and enzyme activity

Description

Investigation of how various aryl hydrocarbon receptor (AhR) agonists affect neprilysin (NEP) expression and enzyme activity in N2a neuroblastoma cells. The study tested both endogenous ligands (L-Kynurenine and FICZ) and exogenous ligands (diosmin and indole-3-carbinol) to determine their effects on NEP, a major endogenous catabolic enzyme of amyloid β. The experiment aimed to establish the cellular mechanisms by which AhR activation could potentially regulate Alzheimer's disease pathology through enhanced Aβ clearance.

TARGET GENE

NEP

MODEL SYSTEM

N2a cells

ESTIMATED COST

TIMELINE

0 months

PATHWAY

AhR signaling pathway

SOURCE

extracted_from_pmid_34522212

PRIMARY OUTCOME

NEP expression and enzyme activity

Scoring Dimensions

📖 Wiki Pages

Protocol

Establish N2a cells cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for NEP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure NEP expression and enzyme activity together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting NEP shifts NEP expression and enzyme activity in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (NEP expression and enzyme activity) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

APOE Isoform Expression Across Glial Subtypes0.743

TREM2-mediated microglial tau clearance enhancement0.618

LRP1-Dependent Tau Uptake Disruption0.600

VCP-Mediated Autophagy Enhancement0.595

Extracellular Vesicle Biogenesis Modulation0.582

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.